|Videos|August 13, 2020
ASCO 2020 Data Updates: Metastatic HER2+ Breast Cancer
Advertisement
Key opinion leaders discuss various trial data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting regarding the management of metastatic HER2-positive breast cancer.
Data from the following clinical trials is discussed:
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).(Lin, ASCO 2020 Abstract 1005)
The recent FDA approvals for relapsed refractory HER2+ MBC:
Trastuzumab deruxtecan in Previously Treated HER2+ Breast Cancer: DESTINY-BREAST01 (Modi, NEJM 2020)
Fam-trastuzumab deruxtecan-nxki
Tucatinib
Neratinib
The potential role of trastuzumab deruxtecan in HER2-low expressing tumors: phase 3, DESTINY-Breast04; NCT03734029
Advertisement
Related to this article
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
3
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
4
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
5